This was the stock's third consecutive day of gains.

Vertex Pharmaceuticals scored a major win with the EU approval of ALYFTREK, expanding its cystic fibrosis treatment access in ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Janus Henderson Investors, an investment management company, released its “Janus Henderson Venture Fund” first quarter 2025 ...

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

The company is gearing up to launch a suite of in-house developed AI products, which are expected to enhance outsourcing ...

Vertex Pharmaceuticals has been making quiet waves lately, popping up on investors’ radars like a biotech whack-a-mole. With ...

Vertex's revenue grew 15% y/y to $178.5 million, slightly beating Wall Street's expectations of $176.9 million (+14% y/y) by a hair, while also decelerating three points from Q3's 18% y/y growth pace.

Vertex isn't giving up though, so I'm not too concerned. Yes the stock is down, but XBI has been crushed since I wrote this article too falling from $97 to $89 (9% down).

A quadrilateral is a four-sided shape, where the sides are straight and meet at four vertices. The prefix “quad” means four. There are several types of quadrilaterals. Can you name them?

Vertex chain code is one of image representation that was introduced by Bribiesca in 1999. Each code in this chain code indicates the number of cell vertices, which are in touch with the bounding ...

Over the past decade, Vertex Pharmaceuticals (VRTX -1.65%) has delivered above-average returns. The secret behind the biotech's success isn't much of a secret.